Company

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
Lepu Medical TechnologySHE: 300003

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical Technology (Beijing) Co., Ltd. (SHE: 300003) announced that MWX205 Injection, a dual‑target small interfering RNA (siRNA) drug independently developed by its controlled subsidiary Shanghai Minwei Biotechnology Co., Ltd.…

IASO Bio's In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Avenzo TherapeuticsDuality Biologics

Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418

MSD's Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26
CancerMerck

MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26

Bayer's Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication
BayerETR: BAYN

Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication

GE Healthcare's Allia IGS Pulse Receives NMPA Clearance for Launch in China
GE HealthcareNASDAQ: GEHC

GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China

Show More